NPR takes a look at tax woes for small-scale devicemakers; Edwards gets FDA OK to start valve trial;

@FierceMedDev: Boston Sci is one step closer to getting Watchman, for irregular heartbeat, on the U.S. market. Item | Follow @FierceMedDev

 @MarkHFierce: We have extended the nomination deadline for the 15 fiercest medical device developers to July 13. Spread the word. Survey | Follow @MarkHFierce

 @DamianFierce: In his first year as CEO of Medtronic, Omar Ishrak took home a healthy $25M. Story | Follow @DamianFierce

> NPR's "Morning Edition" checked in with devicemakers as they prepare for the impending 2.3% tax, checking in with smaller devicemakers who fear the charge could put them out of business. Listen

> The FDA has granted Edwards Lifesciences ($EW) an investigational device exemption to start trials on its Intuity heart valve. News

> Speaking of the device tax, one analyst says that Baxter ($BAX) will likely suffer little from the charge, while Boston Scientific ($BSX) is the "most exposed" devicemaker. Article

> Diagnostic firm Great Basin's molecular-based tuberculosis test has demonstrated 96% accuracy in detecting a treatment-resistant form of the disease. Release

> Masimo ($MASI) has signed a distribution deal with PSS World Medical, getting the company's Pronto-7 handheld hemoglobin checker into the hands of physicians nationwide. More

Pharma News

 @FiercePharma: Glaxo will be our new No. 1 in the Top 10 Pharma Settlements special report. More | Follow @FiercePharma

> Icahn crony could profit off a seat on Forest board. Story

> GSK's Zofran arrhythmia risk leads to new label change. Item

> Bristol-Myers, AZ aim for diabetes glory with Amylin buy. News

> GSK pays $3B to wrap up host of Justice Department claims. Article

Biotech News

 @FierceBiotech: Which biotech will be the next to get swept away in the M&A wave? More | Follow @FierceBiotech

 @JohnCFierceBloomberg counts 5 $1B-plus buyouts so far this year, trending up. Also, some data I've seen suggests licensing $$ shrinking. More | Follow @JohnCFierce

 @RyanMFierce: Google's new cloud platform attracts biotech players, could rival Amazon EC2 in pharma. More | Follow @RyanMFierce

> Bristol-Myers outbids Big Pharma pack and nabs Amylin for $5.3B. Story

> Which biotech will be the next to get swept away in the M&A wave? Article

> GSK, Theravance race rivals with PhIII COPD data on LAMA/LABA combo. News

> Icahn confederate could profit off a seat on Forest board. Item

Biotech IT News

> Boehringer claims 'gamification' win in pharma. News

> Microsoft honors Bristol-Myers, Novartis and Sanofi. Article

> Pfizer boosts online offerings to German docs. Item

 

Suggested Articles

A decade-long study found that patients with early breast cancer may be spared radiation procedures that span the whole breast.

A cell therapy for Parkinson’s disease starts out simple, but quickly gets complicated with the potential for immune responses and cancer mutations.

Johnson & Johnson Vision announced that the worldwide president of its surgical business, Tom Frinzi, plans to retire at the end of this year.